Role of IL-1 Beta in the Development of Human TH17 Cells: Lesson from NLPR3 Mutated Patients IL-17/IL-23 Axis in CAPS Patients
2011

Role of IL-1 Beta in the Development of Human TH17 Cells

Sample size: 57 publication Evidence: moderate

Author Information

Author(s): Lasigliè Denise, Traggiai Elisabetta, Federici Silvia, Alessio Maria, Buoncompagni Antonella, Accogli Andrea, Chiesa Sabrina, Penco Federica, Martini Alberto, Gattorno Marco

Primary Institution: Rheumatology Unit, Second Division of Pediatrics “G. Gaslini” Institute, Genoa, Italy

Hypothesis

Can the deregulated secretion of IL-1β in CAPS patients affect the IL-23/IL-17 axis?

Conclusion

The study supports the central role of IL-1β in the differentiation of TH17 cells in human inflammatory conditions.

Supporting Evidence

  • CAPS patients showed significantly increased IL-17 serum levels compared to healthy controls.
  • Decreased IL-17 serum levels were observed in CAPS patients following IL-1β blockade treatment.
  • MoDCs from CAPS patients exhibited enhanced secretion of IL-1β and IL-23 upon stimulation.

Takeaway

This study shows that a protein called IL-1β helps certain immune cells called TH17 cells grow, especially in patients with a specific genetic condition.

Methodology

The study analyzed serum levels of IL-17 and IL-6 in CAPS, SoJIA patients, and healthy controls, and quantified TH17 cells after stimulation.

Potential Biases

Potential bias due to the specific genetic background of the CAPS patients.

Limitations

The study is limited by the small sample size and the specific patient population.

Participant Demographics

11 CAPS patients (6 CINCA, 5 MWS), 26 SoJIA patients, and 20 healthy controls.

Statistical Information

P-Value

p=0.04 for IL-17 levels comparison

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0020014

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication